NEMP1

Across TCGA pan-cancer cohorts, NEMP1 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated NEMP1 data layer compared with 29 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher NEMP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NEMP1 expression acts as an unfavorable survival marker.

DLBC, HNSC, and CESC are the cancer types where NEMP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
HNSC	OS	Median	III,IV	0.010	0.746	<.001	30	view →
CESC	DFS	Median	II,III,IV	0.144	0.705	.004	18	view →
LUSC	OS	Median	All	0.235	0.676	.021	18	view →
BLCA	DFS	Median	IV	0.083	0.476	.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	All	0.272	0.784	<.001	6	view →
BRCA	OS	Median	All	0.761	0.963	.022	4	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

NEMP1–DLBC (OS)

Open the DLBC breakdown →